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maximal electroshock-induced seizure model was pharma-
codynamic in nature. A special attention is required when 
combining ivabradine with phenytoin due to a pharmacoki-
netic interaction and reduction of the anticonvulsant action 
of phenytoin in mice. The combinations of ivabradine with 
carbamazepine and phenobarbital were neutral from a pre-
clinical viewpoint.




Ivabradine, as a hyperpolarization-activated cyclic nucle-
otide-gated (HCN) channel blocker inhibits directly and 
selectively a depolarizing mixed sodium and potassium 
inward current, called the “funny” current  (If/Ih) in both, 
sino-atrial node and neurons [1–4]. Under physiological 
conditions, any increase or decrease in intracellular cyclic 
adenosine monophosphate (cAMP) level regulates the  If/Ih 
current, producing a shift in the voltage-dependent activa-
tion of the  If/Ih current [5]. Although the physiological role 
of the  Ih current in neurons is still unclear, the  Ih current is 
expected to play a pivotal role in seizure activity.
Experimental evidence indicates that ivabradine pos-
sesses the anticonvulsant properties by elevating, in a dose 
dependent manner, the threshold for electroconvulsions in 
mice and the experimentally determined  TID20 and  TID50 
values (i.e., threshold increasing doses by 20 and 50%) for 
ivabradine were 8.70 and 18.29  mg/kg, respectively [6]. 
Since ivabradine, as an HCN channel blocker, elevates the 
threshold for electroconvulsions in mice, it can be expected 
that the drug will also be able to enhance the anticonvulsant 
Abstract Although the role of hyperpolarization-acti-
vated cyclic nucleotide-gated (HCN) channels in neuronal 
excitability and synaptic transmission is still unclear, it is 
postulated that the HCN channels may be involved in sei-
zure activity. The aim of this study was to assess the effects 
of ivabradine (an HCN channel inhibitor) on the protec-
tive action of four classical antiepileptic drugs (carbamaz-
epine, phenobarbital, phenytoin and valproate) against 
maximal electroshock-induced seizures in mice. Tonic sei-
zures (maximal electroconvulsions) were evoked in adult 
male albino Swiss mice by an electric current (sine-wave, 
25  mA, 0.2  s stimulus duration) delivered via auricular 
electrodes. Acute adverse-effect profiles of the combina-
tions of ivabradine with classical antiepileptic drugs were 
measured in mice along with total brain antiepileptic drug 
concentrations. Results indicate that ivabradine (10  mg/
kg, i.p.) significantly enhanced the anticonvulsant activity 
of valproate and considerably reduced that of phenytoin in 
the mouse maximal electroshock-induced seizure model. 
Ivabradine (10 mg/kg) had no impact on the anticonvulsant 
potency of carbamazepine and phenobarbital in the maxi-
mal electroshock-induced seizure test in mice. Ivabradine 
(10 mg/kg) significantly diminished total brain concentra-
tion of phenytoin and had no effect on total brain valproate 
concentration in mice. In conclusion, the enhanced anti-
convulsant action of valproate by ivabradine in the mouse 
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potency of some classical antiepileptic drugs. Thus, a 
favorable effect observed for ivabradine in combination 
with classical antiepileptic drugs in experimental animals 
could significantly increase our knowledge about neuronal 
mechanisms involved in seizure initiation, propagation and 
amplification in the brain, especially, in these brain regions 
where  Ih currents are abundantly distributed in neurons.
The aim of this study was to assess the influence of 
ivabradine on the protective action of four classical antie-
pileptic drugs (carbamazepine, phenytoin, phenobarbital 
and valproate) in the mouse maximal electroshock-induced 
tonic seizure model. Generally, in the maximal electroshock 
seizure test it is possible to determine whether ivabradine 
was able to enhance or alleviate the anticonvulsant potency 
of the classical antiepileptic drugs in this seizure model, 
which is considered to be an experimental model of tonic-
clonic seizures and partial convulsions with or without 
secondary generalization in humans [7]. Additionally, the 
effects of ivabradine alone and in combination with the 
classical antiepileptic drugs were examined in three behav-
ioral (chimney, passive avoidance, and grip-strength) tests 
to detect any possible impairment of motor coordination, 
disturbances in long-term memory, and changes in skele-
tal muscular strength in animals. To exclude any pharma-
cokinetic interactions for the observed effects in the mouse 
maximal electroshock-induced seizure model between 
ivabradine and the classical antiepileptic drugs, total brain 




Adult male Albino Swiss mice (weighing 22–26 g), after 7 
days of adaptation to laboratory conditions, were randomly 
assigned to experimental groups, each comprised 8 mice. 
All procedures involving animals and their care, described 
in this study, were approved by the First Local Ethics Com-
mittee for Animal Experiments at the Medical University 
of Lublin (License No.: 13/2015), and complied with the 
European Communities Council Directive of 24 November 
1986 (86/609/EEC). All experiments on animals described 
below are in accordance with ARRIVE guidelines. Total 
number of animals used in this study was 320.
Drugs
Ivabradine (Procoralan®, Les Laboratoires Servier, 
Neuilly-sur-Seine, France), carbamazepine (Polpharma, 
Starogard Gdański, Poland), phenobarbital (Polfa, 
Kraków, Poland), phenytoin (Polfa, Warszawa, Poland) 
were suspended in a 1% solution of Tween 80 (Sigma-
Aldrich) in distilled water. Only valproate (sodium salt—
Sigma-Aldrich) was directly dissolved in distilled water. 
All drugs were administered intraperitoneally (ip) as 
follows: phenytoin—120  min, ivabradine and phenobar-
bital—60  min, carbamazepine and valproate—30  min 
before maximal electroshock-induced seizures, behavio-
ral (passive-avoidance, grip-strength and chimney) tests 
and before collection of brains for the measurement of 
antiepileptic drug concentrations, as documented earlier 
[6, 8–10].
Maximal Electroshock Seizure Test
In the maximal electroshock seizure test, mice were chal-
lenged with a current (sine-wave, 25 mA, 50 Hz, 500 V, 
stimulus duration 0.2 s) delivered via ear-clip electrodes 
from a rodent shocker generator (Hugo Sachs Elektronik, 
Freiburg, Germany). The tonic hind limb extension in 
mice was the endpoint. The classical antiepileptic drugs 
administered singly and their combination with ivabra-
dine were tested for their ability to increase the number 
of mice protected from maximal electroconvulsions. Log-
probit method [11] was used to determine median effec-
tive dose  (ED50) values for the antiepileptic drugs tested. 
The mice were injected with ivabradine in doses of 5 and 
10  mg/kg that by themselves did not significantly affect 
the threshold for electroconvulsions [6]. Total number of 
animals used in this procedure was 240.
Measurement of Total Brain Antiepileptic Drug 
Concentrations
The measurement of total brain concentrations of phe-
nytoin and valproate (at doses that corresponded to their 
 ED50 values from the maximal electroshock seizure test) 
was performed by a fluorescence polarization immunoas-
say. The mice received a given antiepileptic drug alone 
and in combination with ivabradine (10 mg/kg), and sub-
sequently, the mice were decapitated. The whole brains of 
mice were removed from the skulls, weighed, harvested 
and homogenized using Abbott buffer (1:2, w/v; Abbott 
Laboratories, North Chicago, IL, USA). The homoge-
nates were centrifuged at 10,000×g for 10  min and the 
supernatant samples of 100  μl were collected and then 
analyzed for phenytoin or valproate content by Abbott 
TDx analyzer, as described earlier [12]. Total brain phe-
nytoin and valproate concentrations are expressed in μg/g 
of wet brain tissue as the means ± S.E.M. (n = 8 mice per 
group). Total number of animals used in this procedure 
was 32.
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Step-Through Passive Avoidance Task
The assessment of any acute adverse effect potential of 
ivabradine (10 mg/kg) alone and in combination with clas-
sical antiepileptic drugs (at doses that corresponded to their 
 ED50 values from the maximal electroshock seizure test) 
with respect to deficits in long-term memory in mice was 
quantified by the step-through passive avoidance task, as 
described earlier [8, 9, 13]. Long-term memory in mice is 
expressed as the median latencies (retention times) with 
25th and 75th percentiles (n = 8 mice per group). Total 
number of animals used in this procedure was 48.
Grip-Strength Test
The assessment of any acute adverse effect potential of 
ivabradine (10 mg/kg) alone and in combination with clas-
sical antiepileptic drugs (at doses that corresponded to their 
 ED50 values from the maximal electroshock seizure test) 
with respect to changes in skeletal muscular strength in 
mice was quantified by the grip-strength test, as published 
elsewhere [8, 9, 14]. The skeletal muscular strength in mice 
is expressed in newtons (N) as the means ± S.E.M. (n = 8 
mice per group). Total number of animals used in this pro-
cedure was 48.
Chimney Test
The assessment of any acute adverse effect potential of 
ivabradine (10 mg/kg) alone and in combination with clas-
sical antiepileptic drugs (at doses that corresponded to 
their  ED50 values from the maximal electroshock seizure 
test) with respect to impairment of motor coordination 
in mice was performed by the use of the chimney test, as 
described earlier [8, 9, 15]. Results from the chimney test 
are expressed as percentage (%) of animals showing motor 
coordination impairment (n = 8 mice per group). Total 
number of animals used in this procedure was 48.
Statistics
Statistical analysis of data from the maximal electroshock 
seizure test was performed either with the log-probit 
method [11] for single comparisons between two  ED50 val-
ues, or with one-way ANOVA, followed by the post-hoc 
Tukey–Kramer test for multiple comparisons among three 
 ED50 values, as described earlier [16]. The unpaired Stu-
dent’s t test was used to statistically compare total brain 
antiepileptic drug concentrations. The Fisher’s exact proba-
bility test was used to analyze qualitative variables from the 
chimney test. The Kruskal–Wallis nonparametric ANOVA 
analyzed data from the passive avoidance task, whereas the 
results from the grip-strength test were statistically verified 
with one-way ANOVA. Statistical significance was estab-
lished at P < 0.05.
Results
Influence of Ivabradine on the Protective Activity 
of Carbamazepine, Phenobarbital, Phenytoin 
and Valproate in the Mouse Maximal Electroshock 
Seizure Model
Ivabradine (10  mg/kg, i.p.) significantly reduced the anti-
convulsant potency of phenytoin by increasing its  ED50 
value from 12.80 ± 0.94 to 17.99 ± 1.07  mg/kg (P < 0.01) 
(F(2;61) = 5.993; P = 0.004; Fig.  1c). On the contrary, 
ivabradine (10  mg/kg, i.p.) considerably potentiated the 
anticonvulsant action of valproate by decreasing its  ED50 
value from 311.2 ± 11.7 to 248.2 ± 18.3  mg/kg (P < 0.05) 
(F(2;61) = 3.456; P = 0.038; Fig.  1d). Ivabradine (5  mg/
kg) had no significant impact on the anticonvulsant action 
of phenytoin and valproate in the mouse maximal elec-
troshock seizure model (Fig.  1c, d). Similarly, ivabradine 
(10 mg/kg, ip) did not significantly alter the anticonvulsant 
action of carbamazepine or phenobarbital in the maximal 
electroshock seizure test in mice (Fig. 1a, b).
Influence of Ivabradine on Total Brain Phenytoin 
and Valproate Concentrations
As measured by fluorescent polarization immunoassay 
method, total brain concentrations of phenytoin (18.0 mg/
kg) administered separately were 2.12 ± 0.24  µg/g of 
wet brain tissue, whereas those of phenytoin (18.0  mg/
kg) in combination with ivabradine (10  mg/kg) were sig-
nificantly reduced, amounting to 1.29 ± 0.27  µg/g of wet 
brain tissue (P < 0.05). In contrast, ivabradine (10  mg/kg) 
had no significant impact on total brain concentration of 
valproate (248.2 mg/kg). In this case, the total brain con-
centrations of valproate (248.2 mg/kg) administered alone 
were 99.6 ± 12.2 µg/g of wet brain tissue and did not differ 
significantly from those for the combination of valproate 
(248.2  mg/kg) with ivabradine (10  mg/kg), which were 
105.3 ± 11.5 µg/g of wet brain tissue.
Effects of Ivabradine Alone and in Combination 
with Various Antiepileptic Drugs on Motor 
Performance, Long-Term Memory, and Skeletal 
Muscular Strength of Animals
Ivabradine (10 mg/kg, i.p.) administered alone and in com-
bination with the studied four classical antiepileptic drugs 
did not disturb long-term memory, alter skeletal mus-
cular strength or impair motor performance in mice, as 
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Fig. 1  a–d Effect of ivabradine 
(IVAB) on the protective activ-
ity of carbamazepine (CBZ), 
phenobarbital (PB), phenytoin 
(PHT), and valproate (VPA) 
against maximal electroshock-
induced seizures in mice. Left 
panel Dose–response function 
for the anticonvulsant (pro-
tective) activity of classical 
antiepileptic drugs [CBZ (a), 
PB (b), PHT (c) and VPA (d)] 
alone and in combination with 
ivabradine (IVAB) in the mouse 
maximal electroshock-induced 
seizure model. Each data point 
represents percent of mice 
protected (n = 8 mice/data point) 
from maximal electroshock-
induced seizures at a given 
dose (in mg/kg). Sigmoidal 
curves are the result of a least 
squares fit of dose–response 
function for each antiepileptic 
drug. Points of intersections 
with the dashed line at 50% 
correspond to approximate 
 ED50 values of antiepileptic 
drugs. Right panel Columns 
represent median effective doses 
 (ED50 in mg/kg ± S.E.M.) of 
antiepileptic drugs that protect 
50% of animals tested against 
maximal electroshock-induced 
seizures in mice. The log-probit 
method was used for calculating 
the  ED50 values and statistical 
analysis of data was performed 
either with log-probit method 
for single comparison (a, b) or 
with one-way ANOVA followed 
by the post-hoc Tukey–Kramer 
test for multiple comparisons 
(c, d). *P < 0.05 and **P < 0.01 
versus control (antiepileptic 
drug + vehicle-treated) animals
Table 1  Effects of ivabradine 
and its combination with four 
classical antiepileptic drugs 
on long-term memory in the 
passive avoidance task, motor 
performance in the chimney test 
and muscular strength in the 
grip-strength test in mice
Results are presented as: median retention times [in seconds (s); with 25th and 75th percentiles in paren-
theses] from the passive avoidance task; mean muscular strengths [in newtons (N) ± S.E.M.] from the grip-
strength test; and percentage (%) of animals with impairment of motor coordination from the chimney test. 
Each experimental group consisted of 8 mice
Treatment (mg/kg) Retention time (s) Muscular strength (N) Motor coordina-
tion impairment 
(%)
Vehicle 180 (180; 180) 1.087 ± 0.067 0
Ivabradine (10) + Vehicle 180 (180; 180) 1.052 ± 0.071 12.5
Carbamazepine (12.5) + Ivabradine (10) 180 (180; 180) 1.049 ± 0.065 0
Phenobarbital (26.9) + Ivabradine (10) 180 (180; 180) 1.048 ± 0.062 0
Phenytoin (18.0) + Ivabradine (10) 180 (180; 180) 1.062 ± 0.072 0
Valproate (248.2) + Ivabradine (10) 177.5 (155.5; 180) 1.063 ± 0.069 12.5
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determined in the passive avoidance task, grip-strength test, 
and chimney test, respectively (Table 1).
Discussion
Results reported in this study indicate that ivabradine, as 
the inhibitor of HCN channels, enhanced the anticonvulsant 
potency of valproate against maximal electroshock-induced 
seizures in mice. Pharmacokinetic study revealed that the 
enhancement of the anticonvulsant potency of valproate (by 
20%) was associated with a non-significant (6%) increase 
in total brain concentration of valproate in mice. Thus, it 
was confirmed that the observed potentiation of the anti-
convulsant potency of valproate in this seizure model by 
ivabradine was pharmacodynamic in nature. To explain the 
observed potentiation of the antiseizure effects of valproate 
by ivabradine, one should consider molecular mechanisms 
of action of both drugs. Ivabradine is a drug that selectively 
and directly blocks the  If/Ih channels in neurons [4, 17]. 
Valproate blocks low-threshold T-type calcium channels, 
enhances GABA-ergic neurotransmission in the brain and 
increases the potassium-induced release of GABA in neu-
rons. Additionally, valproate increases synthesis of GABA 
by activating glutamic acid decarboxylase—a GABA syn-
thesizing enzyme. Valproate activates potassium conduct-
ance and elevates GABA levels in specific brain regions 
by inhibiting GABA-transaminase—an enzyme catalyzing 
GABA degradation (for review see: [18, 19]). Although it 
is difficult to comprehend the exact nature of the synergis-
tic effect from their respective mechanisms of action, this 
study clearly indicates that ivabradine synergistically coop-
erates with valproate in terms of suppression of maximal 
electroshock-induced seizures.
In contrast, ivabradine did not significantly affect the 
anticonvulsant action of carbamazepine and phenobar-
bital in the mouse maximal electroshock seizure model, 
therefore, total brain concentrations of these antiepileptic 
drugs were not estimated in the presented study. On the 
other hand, pharmacokinetic experiments using fluores-
cence polarization immunoassay revealed that ivabradine 
considerably reduced (by 39%) total brain concentrations 
of phenytoin in mice, confirming that a pharmacokinetic 
interaction between drugs was entirely responsible for the 
observed reduction (by 41%) of the  ED50 value of phe-
nytoin in the maximal electroshock-induced seizure test 
in mice when combined with ivabradine. The explana-
tion of this phenomenon may, at least in part, depend on 
the reduction of the heart rate in the mice exposed to the 
combination of phenytoin and ivabradine. Since pheny-
toin belongs to the subclass IB of antiarrhythmic drugs 
[20], and ivabradine is a specific heart rate-lowering 
compound [17, 21], it is possible that the combination of 
these two drugs may significantly reduce the heart rate 
in laboratory mice. Thus, it can be observed a decrease 
in some pharmacokinetic parameters characterizing dis-
tribution of phenytoin in mice, including, its penetration 
through the blood–brain barrier and dispersion of pheny-
toin in the brain tissue. Although this suggestion is highly 
speculative, it can easily explain the observed pharma-
cokinetic reduction in total brain concentrations of phe-
nytoin after co-administration of ivabradine.
Previously, it was documented that phenytoin (applied 
in a dose of 150  mg twice daily) pharmacokinetically 
reduced (by approx. 70%) bioavailability of ivabradine 
(applied in a single dose of 10  mg) in 18 healthy vol-
unteers [22]. Since phenytoin is an inductor of the main 
metabolizing enzyme of ivabradine (CYP3A4), it is 
highly likely that the antiepileptic drug affects pharma-
cokinetics of ivabradine. Of note, ivabradine is metabo-
lized only by CYP3A4 [23], whereas phenytoin mainly 
by CYP2C9 and CYP2C19 [24]. Thus, the mutual induc-
tion of CYP isoenzymes should be borne in mind while 
explaining the observed pharmacokinetic reduction in 
total brain phenytoin concentration in experimental ani-
mals receiving ivabradine. On the other hand, valproate 
is also metabolized by CYP2C9 [24], and ivabradine 
as an inducer of CYP2C9 should also reduce valproate 
concentrations in animals. Since no significant changes 
in valproate concentrations were observed in the mouse 
brain tissue, this pharmacokinetic mechanism was rather 
not responsible for the observed effects. To thoroughly 
characterize pharmacokinetic parameters for the interac-
tion between ivabradine and phenytoin, more advanced 
pharmacokinetic studies, based on simultaneous estima-
tion of distribution, metabolism and elimination of both 
drugs are required.
In this study, we also found that ivabradine combined 
with four classical antiepileptic drugs, at doses corre-
sponding to their  ED50 values from the maximal elec-
troshock seizure test, did not affect acute adverse effects 
produced by classical antiepileptic drugs in the chimney, 
step-through passive avoidance and grip-strength tests in 
mice. Results from these behavioral tests may indirectly 
suggest that the heart rate-lowering effect of the combi-
nation of phenytoin with ivabradine was not so meaning-
ful, permitting the animals to correctly perform all the 
studied behavioral tests without any significant impair-
ment in locomotor activity, learning and skeletal mus-
cular strength in mice. The similar situation was docu-
mented in animals receiving ivabradine in combination 
with carbamazepine, phenobarbital and valproate.
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Conclusion
The application of ivabradine together with valproate 
may be clinically favorable due to the pharmacodynamic 
enhancement of the anticonvulsant potency of the latter 
drug. In contrast, a special attention is advised to patients 
receiving phenytoin with ivabradine because of pharma-
cokinetic reduction of phenytoin concentrations that may 
result in alleviation of protection of the antiepileptic drug 
from seizures. In the case of the combinations of ivabra-
dine with carbamazepine or phenobarbital, no significant 
changes in the anticonvulsant properties of the studied 
antiepileptic drugs are expected. If the results from this 
preclinical study could be translated to clinical settings, 
ivabradine would be combined with classical antiepileptic 
drugs, except for phenytoin.
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